Patents Assigned to Baxter Aktiengesellschaft
  • Process for producing a plasma protein-containing medicament with reduced concentration of citrate and metals
    Patent number: 8709492
    Abstract: There is disclosed a method of preparing a plasma-protein-containing medicament from citrated plasma or from a citrate-containing plasma fraction, the medicament being substantially free from undesired metals, which method comprises the following steps: exchanging the citrate and optionally citrate-bound metals in a plasma-protein-containing solution for a water-soluble mono- or dicarboxylate or for an organic mono- or dicarboxylic acid under non-precipitating conditions, recovering the plasma protein or the plasma proteins, and finishing the medicament.
    Type: Grant
    Filed: June 14, 2005
    Date of Patent: April 29, 2014
    Assignee: Baxter Aktiengesellschaft
    Inventors: Wolfgang Teschner, Yendra Linnau, Sonja Svatos, Herwig Igel
  • Fibrinogen-based tissue adhesive containing an elastase inhibitor
    Patent number: 8425947
    Abstract: The present invention provides a fibrinogen-based tissue adhesive which contains an elastase inhibitor.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: April 23, 2013
    Assignee: Baxter Aktiengesellschaft
    Inventors: Heinz Redl, Johann Eibl, Irmgard Schlag
  • FIBRINOGEN-BASED TISSUE ADHESIVE CONTAINING AN ELASTASE INHIBITOR
    Publication number: 20110190812
    Abstract: The present invention provides a fibrinogen-based tissue adhesive which contains an elastase inhibitor.
    Type: Application
    Filed: February 4, 2011
    Publication date: August 4, 2011
    Applicant: Baxter Aktiengesellschaft
    Inventors: Heinz REDL, Guenther Schlag, Irmgard Schlag, Johann Eibl
  • RECOMBINANT CELL CLONES HAVING INCREASED STABILITY AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20110104758
    Abstract: Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
    Type: Application
    Filed: January 6, 2011
    Publication date: May 5, 2011
    Applicant: Baxter Aktiengesellschaft
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • Fibrinogen-based tissue adhesive containing an elastase inhibitor
    Patent number: 7892802
    Abstract: The present invention provides a fibrinogen-based tissue adhesive which contains an elastase inhibitor.
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: February 22, 2011
    Assignee: Baxter Aktiengesellschaft
    Inventors: Heinz Redl, Guenther Schlag, Irmgard Schlag, legal representative, Johann Eibl
  • Recombinant Cell Clones Having Increased Stability and Methods of Making and Using the Same
    Publication number: 20100317055
    Abstract: Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
    Type: Application
    Filed: August 2, 2010
    Publication date: December 16, 2010
    Applicant: Baxter Aktiengesellschaft
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • RECOMBINANT CELL CLONES HAVING INCREASED STABILITY AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20100221828
    Abstract: Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
    Type: Application
    Filed: May 12, 2010
    Publication date: September 2, 2010
    Applicant: Baxter Aktiengesellschaft
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • RECOMBINANT CELL CLONES HAVING INCREASED STABILITY AND METHODS OF MAKING AND USING SAME
    Publication number: 20090258391
    Abstract: Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
    Type: Application
    Filed: June 19, 2009
    Publication date: October 15, 2009
    Applicant: Baxter Aktiengesellschaft
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • RECOMBINANT CELL CLONES HAVING INCREASED STABILITY AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20090253178
    Abstract: Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
    Type: Application
    Filed: June 19, 2009
    Publication date: October 8, 2009
    Applicant: Baxter Aktiengesellschaft
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • Fibrinogen-Based Tissue Adhesive Containing an Elastase Inhibitor
    Publication number: 20090041748
    Abstract: The present invention provides a fibrinogen-based tissue adhesive which contains an elastase inhibitor.
    Type: Application
    Filed: October 16, 2008
    Publication date: February 12, 2009
    Applicant: Baxter Aktiengesellschaft
    Inventors: Heinz Redl, Guenther Schlag, Irmgard Schlag, Johann Eibl
  • Fibrinogen-based tissue adhesive containing an elastase inhibitor
    Patent number: 7459295
    Abstract: The present invention provides a fibrinogen-based tissue adhesive which contains an elastase inhibitor.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: December 2, 2008
    Assignee: Baxter Aktiengesellschaft
    Inventors: Heinz Redl, Gunther Schlag, Johann Eibl
  • MEDIUM FOR THE PROTEIN-FREE AND SERUM-FREE CULTIVATION OF CELLS
    Publication number: 20080182297
    Abstract: A medium is described for the protein-free and serum-free cultivation of cells, especially mammalian cells, whereby the medium contains a proportion of soy hydrolysate.
    Type: Application
    Filed: August 20, 2007
    Publication date: July 31, 2008
    Applicant: Baxter Aktiengesellschaft
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner, Leopold Grillberger, Artur Mitterer
  • Composition Exhibiting a von Willebrand Factor (vWF) Protease Activity Comprising a Polypeptide Chain with the Amino Acid Sequence AAGGILHLELLV
    Publication number: 20080176312
    Abstract: The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving complexes and methods for their production.
    Type: Application
    Filed: February 15, 2008
    Publication date: July 24, 2008
    Applicant: Baxter Aktiengesellschaft
    Inventors: Bernhard Laemmle, Helena Elisabeth Gerritsen, Miha Furlan, Peter Turecek, Hans-Peter Schwarz, Friedrich Scheiflinger, Gerhard Antoine, Randolf Kerschbaumer, Luigina Tagliavacca, Klaus Zimmermann
  • Factor IX/factor IXa activating antibodies and antibody derivatives
    Patent number: 7279161
    Abstract: An antibody or antibody derivative against factor IX/activated factor IX (FIXa) which increases the procoagulant activity of FIXa.
    Type: Grant
    Filed: March 28, 2005
    Date of Patent: October 9, 2007
    Assignee: Baxter Aktiengesellschaft
    Inventors: Friedrich Scheiflinger, Randolf Kerschbaumer, Falko-Guenter Falkner, Friedrich Dorner, Hans-Peter Schwarz
  • Recombinant cell clones having increased stability and methods of making and using the same
    Publication number: 20070161079
    Abstract: Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
    Type: Application
    Filed: July 7, 2006
    Publication date: July 12, 2007
    Applicant: Baxter Aktiengesellschaft
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • Method for producing a preparation based on fibrinogen and fibronectin as well as protein compositions obtainable according to this method
    Patent number: 7241603
    Abstract: A method for producing protein compositions comprising fibrinogen and fibronectin is disclosed, wherein a fibrinogen and fibronectin-containing starting solution is treated with a precipitating composition which comprises two different components that modify the solubility of fibrinogen and/or fibronectin, so that in a single-step precipitation a precipitate is formed which comprises fibrinogen and fibronectin, and the precipitate formed optionally is further treated by methods known per se.
    Type: Grant
    Filed: November 19, 2002
    Date of Patent: July 10, 2007
    Assignee: Baxter Aktiengesellschaft
    Inventors: Thomas Seelich, Ralf Broermann
  • Nucleic acids encoding factor X analogues having a modified protease cleavage site
    Patent number: 7220569
    Abstract: Nucleic acids encoding factor X analogues are provided that have a modification in the region of the natural Factor Xa activation cleavage site. The modification results in a processing site for a protease not naturally cleaving in this region of the Factor X sequence.
    Type: Grant
    Filed: April 4, 2003
    Date of Patent: May 22, 2007
    Assignee: Baxter Aktiengesellschaft
    Inventors: Michele Himmelspach, Uwe Schlokat, Friedrich Dorner, Andreas Fisch, Johann Eibl
  • Fibrinogen-based tissue adhesive containing an elastase inhibitor
    Publication number: 20060216280
    Abstract: The present invention provides a fibrinogen-based tissue adhesive which contains an elastase inhibitor.
    Type: Application
    Filed: May 30, 2006
    Publication date: September 28, 2006
    Applicant: Baxter Aktiengesellschaft
    Inventors: Heinz Redl, Guenther Schlag, Johann Eibl
  • Recombinant cell clones having increased stability and methods of making and using the same
    Patent number: 7094574
    Abstract: Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
    Type: Grant
    Filed: May 6, 2005
    Date of Patent: August 22, 2006
    Assignee: Baxter Aktiengesellschaft
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • Fibrinogen-based tissue adhesive
    Patent number: 7091015
    Abstract: The present invention provides a fibrinogen-based tissue adhesive which contains an elastase inhibitor.
    Type: Grant
    Filed: August 26, 1998
    Date of Patent: August 15, 2006
    Assignee: Baxter Aktiengesellschaft
    Inventors: Heinz Redl, Guenther Schlag, Johann Eibl